Alector (ALEC)
Market Price (4/9/2026): $2.36 | Market Cap: $258.6 MilSector: Health Care | Industry: Biotechnology
Alector (ALEC)
Market Price (4/9/2026): $2.36Market Cap: $258.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Neurodegenerative Disease Therapeutics, Show more. | Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -127% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -156 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -741% Stock price has recently run up significantly12M Rtn12 month market price return is 145% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -79%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -34%, Rev Chg QQuarterly Revenue Change % is -89% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 127% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -874%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -875% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 184% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -58% High stock price volatilityVol 12M is 107% Key risksALEC key risks include [1] the recent clinical failure of its lead late-stage drug, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Neurodegenerative Disease Therapeutics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -127% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -156 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -741% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 145% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -79%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -34%, Rev Chg QQuarterly Revenue Change % is -89% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 127% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -874%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -875% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 184% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -58% |
| High stock price volatilityVol 12M is 107% |
| Key risksALEC key risks include [1] the recent clinical failure of its lead late-stage drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strategic Repositioning with Alector Brain Carrier (ABC) Platform: A significant driver of the stock's increase was the company's intensified focus on its proprietary Alector Brain Carrier (ABC) platform and an advanced central nervous system (CNS) pipeline. In a February 2026 update, Alector highlighted the platform's ability to enhance therapeutic delivery across the blood-brain barrier for a new generation of drugs, including AL137 for Alzheimer's disease (with an Investigational New Drug (IND) filing targeted for 2026) and AL050 for Parkinson's disease (with an IND filing targeted for 2027). This strategic pivot was positively received by analysts, with BTIG upgrading Alector to a "Buy" rating with a $6 price target on March 10, 2026, citing reduced narrative uncertainty post the latozinemab trial failure. This upgrade contributed to a 7.11% gain in the stock on that day.
2. Robust Financial Runway: Alector reported a strong financial position with approximately $256.0 million in cash, cash equivalents, and investments as of December 31, 2025. This capital is projected to fund operations at least through 2027, providing financial stability and confidence to investors, especially following the significant pipeline adjustments and workforce reductions announced in late 2025.
Show more
Stock Movement Drivers
Fundamental Drivers
The 51.3% change in ALEC stock from 12/31/2025 to 4/9/2026 was primarily driven by a 430.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.56 | 2.36 | 51.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 69 | 21 | -69.5% |
| P/S Multiple | 2.3 | 12.3 | 430.2% |
| Shares Outstanding (Mil) | 103 | 110 | -6.4% |
| Cumulative Contribution | 51.3% |
Market Drivers
12/31/2025 to 4/9/2026| Return | Correlation | |
|---|---|---|
| ALEC | 53.8% | |
| Market (SPY) | -5.4% | 48.2% |
| Sector (XLV) | -3.5% | 44.5% |
Fundamental Drivers
The -20.3% change in ALEC stock from 9/30/2025 to 4/9/2026 was primarily driven by a -74.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302025 | 4092026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.96 | 2.36 | -20.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 81 | 21 | -74.1% |
| P/S Multiple | 3.7 | 12.3 | 235.6% |
| Shares Outstanding (Mil) | 100 | 110 | -8.4% |
| Cumulative Contribution | -20.3% |
Market Drivers
9/30/2025 to 4/9/2026| Return | Correlation | |
|---|---|---|
| ALEC | -18.9% | |
| Market (SPY) | -2.9% | 29.7% |
| Sector (XLV) | 7.8% | 19.7% |
Fundamental Drivers
The 91.9% change in ALEC stock from 3/31/2025 to 4/9/2026 was primarily driven by a 921.8% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4092026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.23 | 2.36 | 91.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 101 | 21 | -79.1% |
| P/S Multiple | 1.2 | 12.3 | 921.8% |
| Shares Outstanding (Mil) | 98 | 110 | -10.3% |
| Cumulative Contribution | 91.9% |
Market Drivers
3/31/2025 to 4/9/2026| Return | Correlation | |
|---|---|---|
| ALEC | 95.1% | |
| Market (SPY) | 16.3% | 28.3% |
| Sector (XLV) | 3.7% | 29.7% |
Fundamental Drivers
The -61.9% change in ALEC stock from 3/31/2023 to 4/9/2026 was primarily driven by a -84.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4092026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.19 | 2.36 | -61.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 134 | 21 | -84.2% |
| P/S Multiple | 3.8 | 12.3 | 220.5% |
| Shares Outstanding (Mil) | 83 | 110 | -24.5% |
| Cumulative Contribution | -61.9% |
Market Drivers
3/31/2023 to 4/9/2026| Return | Correlation | |
|---|---|---|
| ALEC | -61.2% | |
| Market (SPY) | 63.3% | 27.6% |
| Sector (XLV) | 20.8% | 25.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALEC Return | 36% | -55% | -14% | -76% | -17% | 55% | -84% |
| Peers Return | -35% | -18% | 22% | -29% | 14% | 2% | -46% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| ALEC Win Rate | 50% | 33% | 50% | 25% | 50% | 75% | |
| Peers Win Rate | 47% | 39% | 44% | 36% | 56% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ALEC Max Drawdown | -2% | -67% | -59% | -78% | -52% | -2% | |
| Peers Max Drawdown | -43% | -40% | -20% | -43% | -31% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: DNLI, BIIB, ACAD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/9/2026 (YTD)
How Low Can It Go
| Event | ALEC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.5% | -25.4% |
| % Gain to Breakeven | 947.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -73.4% | -33.9% |
| % Gain to Breakeven | 275.3% | 51.3% |
| Time to Breakeven | 259 days | 148 days |
Compare to DNLI, BIIB, ACAD
In The Past
Alector's stock fell -90.5% during the 2022 Inflation Shock from a high on 7/7/2021. A -90.5% loss requires a 947.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Alector (ALEC)
AI Analysis | Feedback
Here are 1-3 brief analogies for Alector:
- Like a startup Biogen, focused on antibody treatments for neurodegenerative diseases.
- Like Amgen or Genentech, but still in the clinical trial phase, developing antibody drugs for conditions like Alzheimer's.
AI Analysis | Feedback
- AL001: A humanized recombinant monoclonal antibody in Phase III clinical trials for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis.
- AL101: A therapy in Phase I clinical trials for neurodegenerative diseases, including Alzheimer's and Parkinson's.
- AL002: A product candidate in Phase II clinical trials for Alzheimer's disease.
- AL003: A product candidate in Phase I clinical trials for Alzheimer's disease.
- AL044: A development-stage therapy targeting MS4A4A, a risk gene for Alzheimer's disease.
AI Analysis | Feedback
Alector (ALEC) is a clinical-stage biopharmaceutical company. At this stage, its revenue primarily comes from collaboration agreements with larger pharmaceutical companies for research, development, and potential commercialization of its drug candidates. Therefore, its major "customers" or financial partners are other companies.
- GlaxoSmithKline plc (symbol: GSK)
- Adimab, LLC
AI Analysis | Feedback
Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
Dr. Rosenthal co-founded Alector in 2013 and has served as its Chief Executive Officer and a member of its Board of Directors since then. He previously co-founded Annexon Biosciences, Inc., where he served as acting Chief Executive Officer and later as Chairman. Dr. Rosenthal also co-founded Rinat Neuroscience Corporation, which discovered and developed the migraine drug Ajovy and was acquired by Pfizer Inc. in 2006. Before his entrepreneurial ventures, he held various roles at Genentech, Inc., ultimately serving as Staff Scientist, where his team discovered the target for the cancer drug Erivedge. He holds a Ph.D. in biology from the Hebrew University of Jerusalem.
Neil Berkley, M.B.A., Chief Financial Officer and Chief Business Officer
Mr. Berkley joined Alector in March 2024 as Chief Business Officer and assumed the role of Interim CFO in June 2025, with his current title listed as Chief Financial Officer and Chief Business Officer. Prior to Alector, he served as Chief Corporate Development Officer at Juvena Therapeutics, Chief Business Officer at AbCellera, and Vice President and Head of Business Development at Halozyme Therapeutics. His career also includes leadership roles at Cadence Pharmaceuticals, Acadia, and GSK. He holds a B.S. in Molecular Biology from the University of California, San Diego, and an M.S. and an M.B.A.
Giacomo Salvadore, M.D., Chief Medical Officer
Dr. Salvadore was appointed Chief Medical Officer effective April 25, 2025, having joined Alector in 2023 as Senior Vice President of Clinical Development. He leads Alector's global clinical development strategy for its late-stage clinical and research portfolios. Dr. Salvadore brings over 15 years of industry experience in leading clinical development for neurology and psychiatry programs.
Hua Long, PhD, DABT, Senior Vice President and Head of Research
Dr. Long leads Alector's research and preclinical organization. In this role, she oversees discovery, nonclinical science, and translational research to advance therapies for neurodegenerative diseases.
Danielle Pasqualone, Ph. D., J.D., General Counsel
Dr. Pasqualone joined Alector in 2019 as the Vice President of Intellectual Property and now serves as General Counsel. She is responsible for overseeing the company's legal function, directing global intellectual property strategy, and providing legal counsel on various transactions, including collaborations.
AI Analysis | Feedback
The key risks for Alector (ALEC) are primarily related to the inherent challenges of being a clinical-stage biopharmaceutical company focused on neurodegenerative diseases.
- Clinical Trial Failure and Regulatory Approval: As a clinical-stage company, Alector's success is entirely dependent on its product candidates successfully navigating and demonstrating safety and efficacy in ongoing and future clinical trials (Phase I, II, and III). A significant portion of drug candidates fail at various stages of clinical development, especially in late-stage trials, or fail to receive regulatory approval from health authorities, which would prevent the company from commercializing its therapies.
- High Development Risk for Neurodegenerative Diseases: Alector's pipeline is focused on neurodegenerative diseases such as Frontotemporal Dementia, Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis. Historically, drug development for these complex neurological conditions has a high rate of failure, presenting significant challenges in demonstrating clinical benefit and safety.
- Reliance on Strategic Collaborations: Alector has strategic collaboration agreements, notably with GlaxoSmithKline plc for the development and commercialization of key monoclonal antibodies like AL001 and AL101. The success of these programs, and potentially the company's financial stability, could be impacted by the ongoing commitment, resources, or strategic direction of its partners, or by the termination of such agreements.
AI Analysis | Feedback
nullAI Analysis | Feedback
Addressable Markets for Alector's Main Products
- Frontotemporal Dementia (FTD): The global market for frontotemporal dementia is projected to increase from $3.25 billion in 2025 to $3.53 billion in 2026, growing at a compound annual growth rate (CAGR) of 8.8%. It is expected to reach $4.99 billion by 2030.
- Alzheimer's Disease: The global Alzheimer's disease market is estimated at $12.4 billion in 2025 and is projected to reach $29.4 billion by 2035, representing a CAGR of 9%.
- Parkinson's Disease: The global Parkinson's disease drugs market size is projected to grow from $7.75 billion in 2025 to $15.77 billion by 2034, at a CAGR of 8.22%.
- Amyotrophic Lateral Sclerosis (ALS): The global Amyotrophic Lateral Sclerosis market is estimated to be valued at $835.8 million in 2025 and is projected to reach $1496.9 million by 2035, with a compound annual growth rate (CAGR) of 6.0%.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Alector (ALEC)
Over the next two to three years, Alector's future revenue growth is anticipated to be driven by the following key factors:
- Advancement and Potential Commercialization of AL101 (Nivisnebart): The progression of AL101, developed in collaboration with GlaxoSmithKline (GSK), through its ongoing Phase 2 PROGRESS-AD clinical trial for early Alzheimer's disease is a significant driver. Positive results from the interim futility analysis expected in the first half of 2026 and subsequent advancement into later-stage clinical development could trigger substantial milestone payments from GSK and pave the way for future product revenue upon commercialization.
- Development and Clinical Entry of Alector Brain Carrier (ABC) Platform Programs: Alector's proprietary Alector Brain Carrier (ABC) platform, designed to enhance the delivery of therapeutics across the blood-brain barrier, represents a strategic focus for future growth. The planned Investigational New Drug (IND) submissions for lead ABC-enabled candidates, such as AL137 for Alzheimer's disease in late 2026-early 2027 and AL050 for Parkinson's disease in 2027, are expected to generate future milestone payments or lead to new collaboration agreements.
- Milestone Payments from the Strategic Collaboration with GlaxoSmithKline (GSK): The existing strategic collaboration agreement with GSK provides a framework for significant potential revenue. This includes up to $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments for partnered programs. The continued progression of AL101 within this collaboration is crucial for realizing these milestone payments.
AI Analysis | Feedback
Share Issuance
- In January 2024, Alector completed an underwritten public offering of 10,869,566 shares of its common stock, generating gross proceeds of $75 million.
- In January 2020, Alector completed an upsized underwritten public offering of 8,350,000 shares of common stock at $25.00 per share, resulting in gross proceeds of $208,750,000.
Inbound Investments
- In July 2021, Alector entered a strategic global collaboration with GlaxoSmithKline (GSK) for the development and commercialization of AL001 and AL101. As part of this agreement, Alector received $700 million in upfront payments and is eligible for up to an additional $1.5 billion in potential milestone payments.
- In November 2024, Alector secured a $50 million credit facility from Hercules Capital to boost its financial flexibility and advance its pipeline.
Capital Expenditures
- Alector reported capital expenditures of -$1 (likely referring to $1 million, given the context of other financial figures in millions) in a recent financial summary.
- Research and development expenses for the full year 2025 were $123.1 million, a decrease from $185.9 million in 2024, reflecting a significant portion of capital deployed towards its drug pipeline.
- The primary focus of ongoing capital deployment and R&D is the Alector Brain Carrier (ABC) platform and its lead candidates, AL137 and AL050, targeting Investigational New Drug (IND) submissions in 2026 and 2027, respectively.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ALEC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.02 |
| Mkt Cap | 3.6 |
| Rev LTM | 546 |
| Op Inc LTM | -26 |
| FCF LTM | -87 |
| FCF 3Y Avg | -70 |
| CFO LTM | -37 |
| CFO 3Y Avg | -52 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.2% |
| Rev Chg 3Y Avg | -0.9% |
| Rev Chg Q | -7.1% |
| QoQ Delta Rev Chg LTM | -1.7% |
| Op Mgn LTM | 9.8% |
| Op Mgn 3Y Avg | 2.8% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 10.3% |
| CFO/Rev 3Y Avg | 9.7% |
| FCF/Rev LTM | 1.0% |
| FCF/Rev 3Y Avg | 6.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.6 |
| P/S | 3.6 |
| P/EBIT | 6.3 |
| P/E | 4.0 |
| P/CFO | 5.2 |
| Total Yield | -5.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -5.3% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.4% |
| 3M Rtn | 4.6% |
| 6M Rtn | 13.9% |
| 12M Rtn | 51.1% |
| 3Y Rtn | -28.3% |
| 1M Excs Rtn | -4.1% |
| 3M Excs Rtn | 6.1% |
| 6M Excs Rtn | 9.0% |
| 12M Excs Rtn | 26.1% |
| 3Y Excs Rtn | -92.2% |
Price Behavior
| Market Price | $2.40 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 02/07/2019 | |
| Distance from 52W High | -27.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.12 | $1.99 |
| DMA Trend | up | up |
| Distance from DMA | 13.1% | 20.3% |
| 3M | 1YR | |
| Volatility | 74.6% | 107.3% |
| Downside Capture | 0.38 | 1.42 |
| Upside Capture | 319.48 | 308.04 |
| Correlation (SPY) | 39.0% | 25.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.44 | 2.63 | 2.38 | 2.26 | 1.58 | 1.64 |
| Up Beta | 8.45 | 5.15 | 5.49 | 3.15 | 0.78 | 1.18 |
| Down Beta | 2.50 | 2.10 | 1.80 | 1.76 | 1.52 | 1.68 |
| Up Capture | 170% | 397% | 413% | 263% | 722% | 408% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 12 | 21 | 32 | 62 | 132 | 379 |
| Down Capture | 189% | 140% | 90% | 210% | 159% | 113% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 10 | 19 | 26 | 52 | 103 | 342 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALEC | |
|---|---|---|---|---|
| ALEC | 148.4% | 107.3% | 1.39 | - |
| Sector ETF (XLV) | 12.6% | 16.8% | 0.54 | 28.3% |
| Equity (SPY) | 29.1% | 17.4% | 1.36 | 26.6% |
| Gold (GLD) | 61.3% | 27.8% | 1.72 | 3.4% |
| Commodities (DBC) | 26.9% | 16.7% | 1.41 | -5.2% |
| Real Estate (VNQ) | 17.7% | 15.4% | 0.86 | 16.7% |
| Bitcoin (BTCUSD) | -10.9% | 43.9% | -0.14 | 19.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALEC | |
|---|---|---|---|---|
| ALEC | -34.0% | 86.6% | -0.08 | - |
| Sector ETF (XLV) | 6.7% | 14.6% | 0.28 | 29.0% |
| Equity (SPY) | 11.4% | 17.0% | 0.52 | 32.2% |
| Gold (GLD) | 22.2% | 17.8% | 1.02 | 5.2% |
| Commodities (DBC) | 11.5% | 18.8% | 0.50 | 0.8% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 28.6% |
| Bitcoin (BTCUSD) | 3.6% | 56.5% | 0.29 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALEC | |
|---|---|---|---|---|
| ALEC | -17.9% | 84.2% | 0.06 | - |
| Sector ETF (XLV) | 10.0% | 16.5% | 0.50 | 33.7% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 34.7% |
| Gold (GLD) | 14.1% | 15.9% | 0.74 | 3.4% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 7.1% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 28.5% |
| Bitcoin (BTCUSD) | 67.1% | 66.9% | 1.06 | 15.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/25/2026 | 7.1% | -10.0% | -11.3% |
| 10/21/2025 | -49.8% | -53.3% | -62.0% |
| 8/7/2025 | 47.3% | 68.5% | 89.0% |
| 5/8/2025 | 12.5% | 6.2% | 38.5% |
| 2/26/2025 | -3.5% | -9.9% | -22.7% |
| 11/6/2024 | 7.6% | -2.2% | -58.8% |
| 8/7/2024 | 3.9% | -1.0% | -1.2% |
| 5/8/2024 | 0.2% | 8.9% | -16.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 8 | 6 |
| # Negative | 10 | 14 | 16 |
| Median Positive | 7.3% | 7.6% | 13.8% |
| Median Negative | -4.8% | -9.4% | -12.8% |
| Max Positive | 47.3% | 68.5% | 89.0% |
| Max Negative | -49.8% | -53.3% | -62.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,027 | ||||||
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Collaboration Revenue | 13.00 Mil | 15.50 Mil | 18.00 Mil | 0 | Affirmed | Guidance: 15.50 Mil for 2025 | |
| 2025 Research and Development Expenses | 130.00 Mil | 135.00 Mil | 140.00 Mil | 0 | Affirmed | Guidance: 135.00 Mil for 2025 | |
| 2025 General and Administrative Expenses | 55.00 Mil | 60.00 Mil | 65.00 Mil | 0 | Affirmed | Guidance: 60.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wong-Sarad, Grace | Principal Accounting Officer | Direct | Sell | 12082025 | 1.21 | 4,753 | 5,751 | 148,808 | Form |
| 2 | Wong-Sarad, Grace | Principal Accounting Officer | Direct | Sell | 12032025 | 1.12 | 8,056 | 9,019 | 142,999 | Form |
| 3 | Rosenthal, Arnon | Chief Executive Officer | Direct | Sell | 12032025 | 1.12 | 104,347 | 116,827 | 2,709,477 | Form |
| 4 | Kenkare-Mitra, Sara | President and Head of R&D | Direct | Sell | 12032025 | 1.12 | 41,687 | 46,673 | 561,650 | Form |
| 5 | Berkley, Neil Lindsay | Chief Bus Ofcr & Interim CFO | Direct | Sell | 12032025 | 1.12 | 37,261 | 41,717 | 419,076 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.